- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03094819
PROTECT2: Diabetes Care - Eye Exam
The PROTECT2 pilot study is a single cohort prospective study to gather pilot data and finalize operational details of the main study.
The PROTECT2 main study is a prospective randomized controlled multi-center three group clinical trial. The primary endpoint is the percentage of participants in each study group obtaining a qualified eye examination within 12 months of their enrollment in the study.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The primary objective of this study is to compare the qualified eye examination rate in two groups of patients with diabetes receiving a new intervention, with the rate in a control group of patients with diabetes receiving usual care only.
Secondary objectives are to:
- Improve our understanding of the barriers to obtaining eye examinations;
- Evaluate the communication between eye care providers (ECP) and referring primary care providers (PCP), as determined by rates of follow-up reports sent and received;
- Characterize eye examinations provided to patients with diabetes;
- Explore the relationships between systemic variables known to affect the severity of diabetic retinopathy and the patient's risk of vision-threatening diabetic retinopathy.
Design and Primary Endpoint
- The pilot study is a single cohort prospective study to gather pilot data and finalize operational details of the main study.
- The main study is a prospective randomized controlled multi-center three group clinical trial. The primary endpoint is the percentage of participants in each study group obtaining a qualified eye examination within 12 months of their enrollment in the study.
Interventions and Duration
Eligible patients will be randomized to one of three groups in a 1:1:2 ratio.
- Group 1. Participants randomized to Group 1 will be the control group. They will be observed while they receive usual eye care without any study intervention.
- Financial Incentive. Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care. They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
- Retinal Care DR Service. Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
All participants, regardless of their group, will be in the study for about one year.
Sample Size and Population Patients meeting the inclusion and exclusion criteria will be recruited at up to four (4) study sites until the sample size of 4,500 participants is enrolled. This includes up to 500 patients at each site in the pilot study, and weighted randomization in the main study to ensure enrollment of approximately 500 patients in the Retinal Care DR Service group at each site to evaluate the operational characteristics of the Retinal Care DR Service in populations representative of those anticipated in commercial use.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104-5065
- Dean McGee Eye Institute
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Diagnosed diabetes using the criteria documented in the 2016 Physician Quality Reporting System (PQRS) Measure Specifications Manual for Claims and Registry Reporting of Individual Measures.
- 18 through 75 years of age
- Have a PCP appointment scheduled within 90 days of the date of medical record review.
Exclusion Criteria:
- Patients not diagnosed with diabetes
- History of photosensitive epilepsy
- Inability or unwillingness of the participant to give verbal or written informed consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Sem intervenção: Group 1
Participants randomized to Group 1 will be the control group.
They will be observed while they receive usual eye care without any study intervention.
|
|
Experimental: Financial Incentive
Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care.
They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
|
Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
|
Experimental: Retinal Care DR
Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision-threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision-threatening diabetic retinopathy.
|
Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Qualified eye examination rate
Prazo: 12 months
|
Percent of participants in each study group obtaining a qualified eye examination.
|
12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
PCP report rate
Prazo: 12 months
|
Percent of eye examinations with a follow-up report sent to the PCP.
|
12 months
|
PCP medical record rate
Prazo: 12 months
|
Percent of eye examinations with a follow-up report sent to the PCP, where the results of the follow-up report are documented in the PCP medical record.
|
12 months
|
Eye examination barriers
Prazo: 12 months
|
Descriptive analysis of barriers to obtaining an eye examination.
|
12 months
|
Increased risk group eye examination rate
Prazo: 12 months
|
Percent of participants at increased risk for vision-threatening diabetic retinopathy who are subsequently seen by an eye care provider.
|
12 months
|
Eye examination findings
Prazo: 12 months
|
Descriptive analysis of eye examination findings for participants at increased risk for vision-threatening diabetic retinopathy.
|
12 months
|
Eye examination components
Prazo: 12 months
|
Descriptive analysis of eye examination components for participants at increased risk for vision-threatening diabetic retinopathy.
|
12 months
|
Eye care costs
Prazo: 12 months
|
Numerical analysis of eye care costs using provider reported and claims data.
|
12 months
|
Risk correlations
Prazo: 12 months
|
Correlation analysis of systemic variables known to affect the severity of diabetic retinopathy and retinal specialist interpretation of participant's risk assessment data.
|
12 months
|
Participant perceptions
Prazo: 12 months
|
Descriptive analysis of participant perceptions of the Retinal Care DR Service.
|
12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Ronald M Kingsley, MD, Dean McGee Eye Institute / University of Oklahoma Health Sciences Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 09-PLN-001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .